Miraomics

Executive Summary

Miraomics is a boutique bioinformatics and computational biology services firm based in Cambridge, MA, specializing in multi-omics integration, spatial transcriptomics, and cell type annotation. The company supports cell therapy and large molecule development by transforming complex genomic data into actionable insights, helping clients accelerate research and maximize the value of their data. Founded in 2018, Miraomics positions itself as an expert partner for biologists and businesses seeking to navigate the growing complexity of multi-dimensional genomic datasets. In a competitive landscape where bioinformatics expertise is increasingly critical for drug development, Miraomics differentiates through its deep specialization in spatial and single-cell analytics, which are essential for understanding tumor microenvironments and immune cell interactions. The company’s service model allows it to adapt quickly to client needs, offering tailored solutions that complement internal R&D capabilities. As precision medicine and combination therapies gain traction, the demand for sophisticated data integration and interpretation services is expected to grow, providing Miraomics with steady revenue opportunities from both emerging biotechs and established pharmaceutical companies.

Upcoming Catalysts (preview)

• Q3 2026Announcement of strategic partnership with a top-20 pharmaceutical company45% success
• Q4 2026Launch of an AI-powered multi-omics integration platform35% success
• Q2 2026Peer-reviewed publication demonstrating clinical utility of spatial transcriptomics in immuno-oncology60% success